Norovirus vaccine developer HilleVax stock climbs 10% following upsized $200M IPO

The IPO had been upsized at least twice over the … HIL-214 is licensed from Japanese drugmaker Takeda (TAK), which holds a roughly 9% stake in HLVX. Healthcare VC firm Frazier Life Sciences …
( read original story …)